ArticleRSC advances2026
Clinical potential for infected wound care: synergistic photothermal-photodynamic therapy using a conjugation-bridge modulated D-A-D porous organic polymer.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porphyrin-based photosensitizers (PSs) often suffer from aggregation-caused quenching (ACQ) due to strong π-π stacking, which severely compromises their therapeutic activity. To address this, we leverage the inherently rigid and distorted frameworks of porous organic polymers (POPs) to physically impede such detrimental stacking, thereby preserving the photoactivity of the embedded porphyrin units. By employing a conjugation-bridge engineering strategy, we synthesized a series of porphyrin-based conjugated microporous polymers (CMPs). Among them, the optimal material, TPA-POR, is constructed from an electron-donating TPA unit, specifically, 1,1',1″-(nitrilotris(benzene-4,1-diyl))tris(ethan-1-one) and electron-accepting triazine nodes, denoted as 6,6',6″,6‴-(porphyrin-5,10,15,20-tetrayltetrakis(benzene-4,1-diyl))tetrakis(1,3,5-triazine-2,4-diamine). In this architecture, the porphyrin components serve as the electron-donor cores linked to the triazine units, consistent with their well-known role as PSs. This molecular design gives TPA-POR a distinct donor-acceptor-donor (D-A-D) topology. This rational design confers multiple integrated advantages that synergistically address the key challenges in phototherapy. The inherently positive charge of the structure allows for precise electrostatic targeting to bacterial surfaces, which not only concentrates the therapeutic agent but also critically shortens the diffusion path for short-lived ROS, maximizing their localized impact. TPA-POR exerts its antibacterial effect through dual photodynamic pathways. Its Type I mechanism efficiently generates ROS, such as hydroxyl radicals (˙OH), enabling effective therapy even in hypoxic microenvironments. Concurrently, the Type II pathway provides complementary activity under oxygen-replete conditions. This dual capability reduces reliance on ambient oxygen, overcoming a key limitation of conventional photodynamic therapy. Furthermore, these photodynamic actions are synergized by the material's intrinsic photothermal properties and its rigid, nanostructured surface, which promotes physical interaction with bacteria. Together, these integrated mechanisms ensure potent and reliable efficacy across diverse oxygen tensions. Consequently, TPA-POR exhibits potent antimicrobial activity, achieving near-complete inactivation of both
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.